August 14, 2024 04:06 PM EDTUpdated August 15, 05:49 AM

FDA warning letter targets doctor who worked on a Takeda Phase 3 study

Zachary Brennan

Senior Editor

Back in January, Takeda won approval for a new indication for its primary immunodeficiency drug HyQvia, this time as a treatment for a rare autoimmune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA warning letter targets doctor who worked on a Takeda Phase 3 study

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

Roivant unveils its next deal, hoping for TL1A-sized potential from a shelved Bayer lung disease therapy

Roche's dual GLP-1/GIP results show promising weight loss, but also high rates of vomiting

Adicet follows other cell therapy biotechs in autoimmune pivot

Congress spars over whether the Biosecure Act is an overdue crackdown or a rushed witch hunt

FDA warn­ing let­ter tar­gets doc­tor who worked on a Take­da Phase 3 study

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA warning letter targets doctor who worked on a Takeda Phase 3 study